SPRO
What one share of Spero Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. Since our inception in 2013, we have focused our efforts and financial resources on acquiring and developing product and technology rights, building our intellectual property portfolio and conducting research and development activities for our product candidates.
Spero Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.82 |
|---|---|
| Profit | $0.13 |
| Cash and investments | $0.87 |
| Book value | $0.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.07 | −$95.87 | $2.66 | −$95.43 | — | — |
| 2017 | $0.77 | −$17.82 | $0.01 | −$15.13 | — | — |
| 2018 | $0.25 | −$2.60 | $0.15 | −$2.63 | — | $6.71 |
| 2019 | $1.00 | −$3.35 | $0.02 | −$2.77 | — | $3.89 |
| 2020 | $0.42 | −$3.52 | $0.01 | −$3.84 | — | $4.51 |
| 2021 | $0.59 | −$2.91 | — | −$2.08 | — | $2.73 |
| 2022 | $1.42 | −$1.23 | — | −$0.21 | — | $1.45 |
| 2023 | $1.96 | $0.43 | — | −$0.62 | — | $2.02 |
| 2024 | $0.89 | −$1.27 | — | −$0.43 | — | $0.84 |
| 2025 | $1.13 | $0.15 | — | −$0.21 | — | $1.05 |